Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors

Maurice Y. Nahabedian, Robert A. Cohen, Michael F. Contino, Theresa M. Terem, William H. Wright, Michael W. Berns, Alan G. Wile

Research output: Contribution to journalArticlepeer-review

Abstract

This study was designed to evaluate the interaction of photodynamic therapy (PDT) and chemotherapy in an animal model. PDT is based on the interaction of hematoporphyrin derivative and red light of the appropriate wavelength (630 nm) and intensity. Two tumor models were utilized: C3H/Km mice bearing the RIF-1 tumor and BALB/c mice bearing the EMT-6 tumor. Tumor-bearing mice were treated with either cisplatin (DDP), doxorubicin (ADM), PDT, or a combination of drug and PDT. It was demonstrated that the RIF-1 tumor was sensitive to DDP and insensitive to both PDT and ADM. There was no additional antitumor effect when either drug was combined with PDT. The EMT-6 tumor was moderately sensitive to PDT and mildly sensitive to both DDP and ADM. Although the addition of DDP did not potentiate tumor destruction, the addition of ADM significantly enhanced the effect of PDT (P = .01). The enhanced activity of the combination of PDT and ADM appeared to be the result of increased activity of ADM alone, when illuminated with red (630 nm) light. This potentiation may be due to a photochemical process or may be secondary to the mild hyperthermia generated by illumination with the laser. This study demonstrates that PDT combined with cytotoxic chemotherapy is well tolerated in these animals and that certain combinations of PDT and chemotherapy may result in an enhanced tumoricidal effect. [J Natl Cancer Inst 1988;80:739-743]

Original languageEnglish (US)
Pages (from-to)739-743
Number of pages5
JournalJournal of the National Cancer Institute
Volume80
Issue number10
DOIs
StatePublished - Jul 20 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors'. Together they form a unique fingerprint.

Cite this